NCT04944901View on ClinicalTrials.gov

28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 2, 2021

Primary Completion Date

March 3, 2022

Study Completion Date

March 3, 2022

Conditions

Autistic Disorder

Interventions

DRUG

SB-121

SB-121 is a formulation of L. reuteri

DRUG

Placebo

Placebo oral formulation

Trial Locations (1)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors

lead

Scioto Biosciences, Inc.

INDUSTRY

NCT04944901 - 28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder | Biotech Hunter | Biotech Hunter